The FDA disclosed briefing documents for the meeting Tuesday of the Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee meeting. Panelists from PDAC and DSaRM will take up the matter of the NDA for the esketamine 28-mg single-use nasal spray device, submitted by New Brunswick, N.J.-based Johnson & Johnson company Janssen Pharmaceuticals Inc., as a therapy for treatment-resistant depression.